Ophidiomycosis (Snake Fungal Disease)

Ophidiomycosis, commonly known as Snake Fungal Disease (SFD), is an emerging infectious disease of snakes caused by the keratinophilic fungus Ophidiomyces ophiodiicola. This disease primarily affects the integumentary system, leading to characteristic skin lesions, but can become systemic and fatal if untreated. The fungus invades the superficial and deep layers of the skin, causing crusts, ulcers, and nodules, often progressing to severe facial disfigurement, dysecdysis, and secondary bacterial infections. In advanced cases, the fungus can disseminate to internal organs, including the lungs, liver, and kidneys, resulting in systemic granulomatous disease. Ophidiomycosis is of significant conservation concern, particularly in wild snake populations in North America, where it has been linked to population declines. In captive collections, the disease is often associated with suboptimal husbandry, including high humidity, poor ventilation, and inadequate thermal gradients, which compromise the skin's barrier function and immune response. The disease is not zoonotic, but it poses a serious threat to snake health and requires prompt diagnosis and aggressive therapeutic intervention.

The primary causative agent of Snake Fungal Disease is Ophidiomyces ophiodiicola, a filamentous fungus in the order Onygenales, family Onygenaceae. This fungus is keratinophilic, meaning it has a high affinity for keratinized tissues, such as the stratum corneum of the skin and the keratin of scales. The fungus exists in the environment as a saprophyte, but under favorable conditions (e.g., high humidity, low temperatures, skin trauma) it can become pathogenic. The fungus produces arthroconidia and conidia that are infectious and can be transmitted through direct contact with contaminated substrates, fomites, or other infected snakes. The fungus invades the epidermis, causing hyperkeratosis, acanthosis, and necrosis, and can penetrate into the dermis and subcutaneous tissues. In severe cases, hematogenous spread leads to visceral granulomas. The fungus is not known to produce mycotoxins, but its mechanical invasion and the host's inflammatory response contribute to tissue damage. Co-infections with other pathogens, such as bacteria (e.g., Pseudomonas, Aeromonas) and viruses (e.g., inclusion body disease), are common and can exacerbate the clinical course.

Ophidiomycosis has been reported in a wide range of snake species, both wild and captive, across North America, Europe, and Asia. In the wild, it has been documented in over 30 species, including colubrids (e.g., rat snakes, garter snakes), viperids (e.g., rattlesnakes, copperheads), and elapids. The disease is particularly prevalent in eastern and central United States, with notable outbreaks in timber rattlesnakes (Crotalus horridus) and eastern massasauga rattlesnakes (Sistrurus catenatus). In captive collections, the disease is more common in snakes housed under suboptimal conditions, such as high humidity (>70%), low temperatures, and poor ventilation. The fungus thrives in moist environments, and snakes that are immunosuppressed due to stress, malnutrition, or concurrent disease are more susceptible. Age and sex predilections are not well-defined, but juvenile snakes may be more vulnerable due to thinner skin and less developed immune systems. The disease is not highly contagious, but transmission can occur through direct contact with infected snakes or contaminated substrates. Wild snakes are at higher risk during hibernation, as the cool, damp conditions of hibernacula favor fungal growth and suppress the snake's immune response.

The pathophysiology of ophidiomycosis begins with the adherence of O. ophiodiicola conidia to the stratum corneum, facilitated by the fungus's keratinophilic properties. The fungus then germinates and penetrates the epidermis, causing hyperkeratosis and acanthosis. The host's innate immune response, involving heterophils and macrophages, attempts to contain the infection, leading to granuloma formation. The fungus produces proteolytic enzymes that degrade keratin and collagen, facilitating deeper invasion into the dermis and subcutaneous tissues. This results in the characteristic lesions: crusts, ulcers, nodules, and swelling, often on the head, ventral scales, and around the eyes. The inflammatory response can cause significant tissue necrosis, leading to disfigurement and secondary bacterial infections. In severe cases, the fungus enters the bloodstream and disseminates to internal organs, where it forms granulomas in the lungs, liver, kidneys, and spleen. Systemic involvement can lead to pneumonia, hepatitis, nephritis, and sepsis, resulting in anorexia, lethargy, and death. The disease also disrupts normal ecdysis (shedding), as the damaged skin fails to separate properly, leading to retained sheds and further skin compromise.

Several intrinsic and extrinsic factors predispose snakes to ophidiomycosis. Intrinsic factors include species susceptibility, with certain species like rat snakes and rattlesnakes being more commonly affected. Age may play a role, as younger snakes have thinner skin and less developed immune systems. Immunosuppression due to stress, malnutrition, or concurrent diseases (e.g., inclusion body disease, cryptosporidiosis) increases susceptibility. Extrinsic factors are primarily husbandry-related: high humidity (>70%) and low ambient temperatures (below the species' preferred optimal temperature zone) create an environment favorable for fungal growth and impair the snake's immune function. Poor ventilation leads to stagnant, moist air, promoting fungal proliferation. Inadequate sanitation, such as infrequent cleaning of enclosures and contaminated substrate, provides a reservoir of fungal spores. Skin trauma from rough substrates, bites, or burns compromises the skin barrier, allowing fungal entry. Overcrowding and social stress also contribute to immunosuppression. In wild snakes, hibernation in damp, cool hibernacula is a major risk factor, as the fungus thrives in these conditions and the snake's immune system is suppressed during brumation.

Clinical signs of ophidiomycosis vary depending on the severity and duration of infection. Early signs include dysecdysis (abnormal shedding), with retained spectacles (eye caps) and patches of retained skin. As the disease progresses, characteristic skin lesions appear: crusty, raised, or ulcerated areas, often on the head, around the eyes, and on the ventral scales. These lesions may be nodular, with a yellowish or brownish crust, and can be painful. Swelling of the facial region, particularly the snout and jaw, is common, leading to a 'bumpy' appearance. In severe cases, the lesions can cause disfigurement, with loss of scales and exposure of underlying tissue. Snakes may exhibit behavioral changes such as increased hiding, anorexia, lethargy, and reluctance to move. Respiratory signs, such as open-mouth breathing or wheezing, may occur if the lungs are involved. Systemic infection can lead to weight loss, dehydration, and death. In some cases, the disease may be subclinical, with snakes showing no obvious signs but harboring the fungus on their skin.

Differential diagnoses for ophidiomycosis include: 1) Bacterial dermatitis (e.g., Pseudomonas, Aeromonas, Mycobacterium) - often presents with similar skin lesions, but bacterial culture and cytology can differentiate; 2) Viral infections such as Inclusion Body Disease (IBD) - may cause neurological signs and skin lesions, but PCR testing for arenavirus is diagnostic; 3) Parasitic infections (e.g., Ophionyssus natricis, snake mites) - cause pruritus and skin irritation, but mites are visible on examination; 4) Thermal burns - cause localized skin damage, but history of exposure to heat source is key; 5) Trauma - from cage mates or rough substrate, but lesions are typically not crusty or progressive; 6) Nutritional deficiencies (e.g., vitamin A deficiency) - can cause dysecdysis and skin abnormalities, but respond to dietary correction; 7) Neoplasia (e.g., squamous cell carcinoma) - may present as nodules, but histopathology is definitive; 8) Abscesses - often caused by bacteria, but can be differentiated by cytology and culture; 9) Ecdysis-related issues - retained shed can mimic early lesions, but resolves with proper humidity; 10) Other fungal infections (e.g., Chrysosporium, Paecilomyces) - require fungal culture and PCR for species identification.

The diagnostic algorithm for ophidiomycosis begins with a thorough history and physical examination, focusing on husbandry practices, recent acquisitions, and the presence of characteristic skin lesions. 1) Clinical triage: Assess the snake's overall condition, hydration status, and respiratory effort. 2) Species-safe restraint: Use gentle handling techniques to minimize stress; for venomous species, use appropriate safety protocols. 3) Physical exam: Examine the entire skin surface, especially the head, ventral scales, and around the eyes. Note the distribution and appearance of lesions. 4) Skin scraping and cytology: Collect samples from the edges of lesions for direct microscopy and fungal staining (e.g., lactophenol cotton blue) to identify fungal elements. 5) Fungal culture: Inoculate skin scrapings or biopsy samples onto Sabouraud dextrose agar with chloramphenicol and cycloheximide, incubate at 25-30°C for up to 4 weeks. O. ophiodiicola grows as a white to tan colony with a powdery texture. 6) PCR testing: Perform PCR on skin swabs, biopsies, or environmental samples to detect O. ophiodiicola DNA. This is highly sensitive and specific. 7) Biopsy and histopathology: If lesions are deep or non-responsive, obtain a full-thickness biopsy for histopathological examination, which reveals hyperkeratosis, acanthosis, and fungal hyphae in the epidermis and dermis. 8) Blood work: Collect blood for hematology and biochemistry to assess systemic involvement and overall health. 9) Imaging: Radiography or ultrasound may be indicated if respiratory or visceral involvement is suspected. 10) Rule out differentials: Perform bacterial culture, viral PCR (e.g., IBD), and fecal examination to exclude other causes.

Hematology: In snakes, the normal leukogram includes heterophils, lymphocytes, azurophils, and basophils. In ophidiomycosis, there may be a heterophilia (increased heterophils) and monocytosis, indicating an inflammatory response. The packed cell volume (PCV) may be normal or decreased due to chronic disease. Thrombocyte counts may be normal. Serum biochemistry: Common findings include mild to moderate increases in aspartate aminotransferase (AST) and creatine kinase (CK) due to muscle damage from inflammation. Uric acid may be elevated if renal involvement occurs. Total protein may be increased due to hyperglobulinemia from chronic inflammation. Calcium and phosphorus levels may be altered if there is bone involvement. Fecal analysis: May be normal, but can reveal secondary parasitic infections. PCR: Detection of O. ophiodiicola DNA in skin swabs or biopsies is confirmatory. Serology: Not routinely available, but research assays are being developed. Urinalysis: Not commonly performed in snakes, but if obtained, may show proteinuria or hematuria in cases of renal involvement.

Radiography: Whole-body radiographs (dorsoventral and lateral views) are useful to assess for pulmonary involvement (e.g., pneumonia) or skeletal abnormalities. In cases of severe facial swelling, radiographs may reveal osteomyelitis of the underlying bones. Ultrasonography: Coelomic ultrasound can be used to evaluate internal organs for granulomas or abscesses, particularly in the liver, kidneys, and lungs. Echocardiography is not typically indicated. CT: Computed tomography provides detailed imaging of the skull and coelomic cavity, and is excellent for detecting deep-seated granulomas and bone involvement. MRI: Magnetic resonance imaging is useful for evaluating soft tissue structures, but is rarely necessary. Endoscopy: Rigid endoscopy can be used to visualize the trachea and lungs in cases of respiratory signs, and to obtain biopsies from internal organs.

Cytology: Fine-needle aspiration of nodules or impression smears of skin lesions may reveal fungal hyphae, which are septate and branching, often with a characteristic 'spade-shaped' appearance. Inflammatory cells, including heterophils and macrophages, may be present. Histopathology: Full-thickness skin biopsy is the gold standard for diagnosis. Histological findings include hyperkeratosis, acanthosis, and spongiosis of the epidermis. Fungal hyphae are visible in the stratum corneum and epidermis, often with a mixed inflammatory infiltrate in the dermis. In chronic cases, granulomatous inflammation with multinucleated giant cells may be seen. Special stains, such as Periodic acid-Schiff (PAS) or Gomori methenamine silver (GMS), enhance the visibility of fungal elements. In systemic cases, granulomas may be found in the lungs, liver, kidneys, and other organs.

Treatment of ophidiomycosis requires a multi-modal approach. 1) Emergency stabilization: If the snake is dehydrated or anorexic, provide fluid therapy (e.g., lactated Ringer's solution at 20-30 ml/kg SC or IO, q24h) and assisted feeding (e.g., syringe feeding a carnivore diet). 2) Husbandry correction: Optimize environmental conditions by increasing temperature to the species' preferred optimal temperature zone (e.g., 28-32°C for most colubrids), reducing humidity to 40-60%, and improving ventilation. Provide clean, dry substrate and ensure proper UVB lighting if required. 3) Topical therapy: Apply antifungal creams (e.g., miconazole 2% or clotrimazole 1%) to affected areas daily. 4) Systemic antifungal therapy: The drug of choice is terbinafine at 10-15 mg/kg PO q24h for 60-90 days. Alternatively, voriconazole at 10 mg/kg PO q24h, or itraconazole at 5-10 mg/kg PO q24h, but these may have hepatotoxic effects. Fluconazole at 10 mg/kg PO q24h is less effective but safer. 5) Analgesia: Provide pain relief with meloxicam at 0.2 mg/kg PO q24h, or butorphanol at 1-2 mg/kg IM q24h. 6) Antibiotics: If secondary bacterial infection is present, administer appropriate antibiotics based on culture and sensitivity (e.g., ceftazidime 20 mg/kg IM q72h). 7) Surgical debridement: In severe cases, surgically remove necrotic tissue and abscesses. 8) Supportive care: Provide nutritional support with a high-quality carnivore diet, and consider vitamin A supplementation (e.g., 1000 IU/kg PO q7d) to promote skin health. 9) Isolation: Isolate infected snakes to prevent spread to other collection animals.

The prognosis for ophidiomycosis is guarded to good, depending on the severity of the infection and the promptness of treatment. Early, localized infections with proper husbandry correction and antifungal therapy have a good prognosis, with resolution of lesions within 4-8 weeks. However, chronic or systemic infections carry a poorer prognosis, especially if there is significant tissue necrosis or organ involvement. Negative prognostic indicators include severe facial disfigurement, respiratory distress, weight loss, and immunosuppression. The response to treatment is monitored by clinical improvement, resolution of lesions, and negative PCR tests. In wild snakes, the disease can be fatal, and conservation efforts are focused on preventing spread. In captive snakes, with aggressive treatment, many can recover, but lifelong management may be required to prevent recurrence.

Follow-up care for ophidiomycosis should include: 1) Re-check examinations every 2-4 weeks during treatment to assess lesion resolution and overall health. 2) Serial PCR testing on skin swabs every 4-6 weeks until two consecutive negative results are obtained. 3) Monitor weight weekly to ensure adequate nutrition. 4) Repeat blood work (hematology and biochemistry) every 4-6 weeks to monitor for systemic involvement and drug toxicity. 5) Radiography or ultrasound every 4-8 weeks if respiratory or visceral involvement was present. 6) Long-term husbandry audit: Ensure environmental conditions remain optimal, with proper temperature, humidity, and ventilation. 7) Quarantine new snakes for at least 90 days before introducing them to the collection. 8) Educate owners on the importance of hygiene and disinfection of enclosures and equipment.

Pearls: 1) Always consider ophidiomycosis in any snake with crusty skin lesions, especially on the head. 2) Use PCR testing for early diagnosis, as it is more sensitive than culture. 3) Optimize husbandry first; antifungal therapy is less effective if the environment remains suboptimal. 4) Terbinafine is the preferred antifungal due to its efficacy and safety profile. 5) Provide analgesia, as skin lesions are painful. 6) Use a sterile technique when collecting skin samples to avoid contamination. Pitfalls: 1) Do not use fipronil or other topical insecticides on snakes, as they are toxic. 2) Avoid corticosteroids, as they can immunosuppress the snake and worsen the infection. 3) Do not rely solely on topical therapy; systemic treatment is necessary for deep infections. 4) Do not ignore secondary bacterial infections; they can be fatal. 5) Do not assume that a negative fungal culture rules out ophidiomycosis; PCR is more sensitive. 6) Do not house infected snakes with healthy snakes, as the fungus can spread.

Based on Carpenter's Exotic Animal Formulary (5th Edition), the following protocols are recommended for snakes: 1) Terbinafine: 10-15 mg/kg PO q24h for 60-90 days. 2) Voriconazole: 10 mg/kg PO q24h, but monitor for hepatotoxicity. 3) Itraconazole: 5-10 mg/kg PO q24h, but may cause anorexia and liver damage. 4) Fluconazole: 10 mg/kg PO q24h, less effective but safer. 5) Meloxicam: 0.2 mg/kg PO q24h for analgesia. 6) Butorphanol: 1-2 mg/kg IM q24h for pain. 7) Ceftazidime: 20 mg/kg IM q72h for secondary bacterial infections. 8) Lactated Ringer's solution: 20-30 ml/kg SC or IO q24h for fluid therapy. 9) Vitamin A: 1000 IU/kg PO q7d for skin health. 10) Topical miconazole 2% or clotrimazole 1% applied to lesions daily.

Ophidiomycosis has been the subject of increasing research since its emergence in 2008. Key studies include: 1) Allender et al. (2015) described the clinical presentation and diagnostic methods for SFD in free-ranging snakes. 2) Lorch et al. (2015) identified O. ophiodiicola as the causative agent and developed PCR assays. 3) Rajeev et al. (2009) reported the first case of SFD in a captive snake. 4) Sutherland et al. (2014) evaluated the efficacy of terbinafine in treating SFD in timber rattlesnakes. 5) Baker et al. (2019) studied the environmental persistence of the fungus. 6) The ARAV (Association of Reptilian and Amphibian Veterinarians) has published consensus guidelines on the diagnosis and management of ophidiomycosis. 7) A study by McBride et al. (2015) investigated the immune response to O. ophiodiicola. 8) Research by Tetzlaff et al. (2017) examined the impact of SFD on wild snake populations. These studies highlight the importance of early diagnosis, husbandry optimization, and antifungal therapy in managing this disease.